


COVID-19 Vaccine Review

Prepared by the Northwest Portland Area Indian Health Board (NPAIHB)

Updated 3/1/2021



Vaccine developer:	Pfizer	Moderna	Johnson & Johnson	AstraZeneca	Novavax
How it works	Messenger RNA	Messenger RNA	Inactivated Adeno-virus base (Non-replicating vector vaccine)	Inactivated Adeno-virus base (Non-replicating vector vaccine)	Protein-based (recombinant nanoparticle tech)
Date approved/Expected approval	December 11, 2020	December 18, 2020	February 27, 2021	Has not submitted application for EUA in U.S. yet, but possibly in April	Has not submitted application for EUA in U.S. yet. Currently in phase 3 clinical trials
Efficacy in preventing COVID-19 related hospitalization and death	All five vaccines (Pfizer, Moderna, Johnson & Johnson, AstraZeneca and Novavax) have demonstrated efficacy in preventing severe COVID-19 disease, hospitalizations and deaths. Out of 75,000 people who have received these vaccines as part of research studies, <u>no one</u>, has died from COVID-19.				
What percentage of people did it protect from getting infected in clinical studies?	95% efficacy to prevent symptomatic COVID-19 infection after 2 doses	94.1% efficacy to prevent symptomatic COVID-19 infection after 2 doses; 86.4% for those ≥ 65	66-72% efficacy to prevent symptomatic COVID-19 infection after 1 dose; 85% efficacy in preventing severe disease	70.4% efficacy to prevent symptomatic COVID-19 infection after 2 doses	89.3% efficacy to prevent symptomatic COVID-19 infection after 2 doses in UK, 85.6% for B.117 strain
How many shots do you need?	Two doses, 3 weeks (or 21 days) apart	Two doses, 4 weeks (or 28 days) apart	One dose	Two doses, 4 weeks (or 28 days) apart	Two doses, 3 weeks (or 21 days) apart
What are the potential side effects?	Fatigue, headache, chills, muscle aches, especially after the second dose	Fever, muscle aches, headaches lasting a few days. Effects worse after second dose	Fatigue, headache, muscle aches, nausea and injection site pain	Injection site pain, fever, muscle aches, headache	Fatigue, headache, muscle aches and injection site pain
Storage	-112°F to -76°F (before mixing, vaccine may be stored at 36°F to 46°F for up to 120 hours or 5 days)	-13°F to 5°F (vaccine vials may be stored at 36°F to 40°F for 1 month or 30 days)	36° to 46°F (may be stored at 36° to 46°F for at least 3 months)	36°F to 46°F (may be stored at 36°F to 46°F for at least 6 months)	36°F to 46°F (ready to use)



Summary is continued on the other side



Vaccine developer:	Pfizer	Moderna	Johnson & Johnson	AstraZeneca	Novavax
Who can receive this vaccine?	16 years and older	18 years and older	18 years and older	18 years and older	18 years and older
What about pregnant and breastfeeding women?	The vaccine has not yet been studied in pregnant or lactating women. Pregnant women are allowed to get the vaccine, but should first consult with their doctor. mRNA vaccines are not thought to be a risk to the breastfeeding infant	The vaccine has not yet been studied in pregnant or lactating women. Pregnant women are allowed to get the vaccine, but should first consult with their doctor. mRNA vaccines are not thought to be a risk to the breastfeeding infant	The vaccine has not yet been studied in pregnant or lactating women. Pregnant women are allowed to get the vaccine, but should first consult with their doctor.	The vaccine has not yet been studied in pregnant or lactating women. Pregnant women are allowed to get the vaccine, but should first consult with their doctor. The vaccine is not considered to be a risk to the breastfeeding infant	Not yet available
Who should not get this vaccine?	Caution and consultation should be taken with persons who have a history of serious allergic reactions. Contraindicated in people with prior reactions to vaccine ingredients	Caution and consultation should be taken with persons who have a history of serious allergic reactions. Contraindicated in people with prior reactions to vaccine ingredients	Contraindicated in people with prior reactions to vaccine ingredients	The vaccine should not be given to those who have had a previous severe allergic reaction to a previous dose of the same COVID-19 vaccine or an ingredient in the COVID-19 vaccine	Not yet available
Any significant side effects?	During December 14–23, 2020, there were 21 cases of anaphylaxis after the first dose. 4 cases of Bell's palsy in clinical trial vaccine group	During December 21, 2020–January 10, 2021, there were 10 cases of anaphylaxis after the first dose. 3 cases of Bell's palsy in clinical trial vaccine group	One case of hives and swelling of the lips, one case of severe pain in the injected arm, and one case of generalized weakness, fever, and headache	Four total serious adverse events, including one case of transverse myelitis	Not yet available
What about people with lowered immune function and autoimmune diseases?	Ok for people whose immune function is lowered by HIV, immunosuppressing drugs, or autoimmune disease. People with these conditions may still get the vaccine if they have no other contraindications. There is limited safety data in this group	Ok for people whose immune function is lowered by HIV, immunosuppressing drugs, or autoimmune disease. People with these conditions may still get the vaccine if they have no other contraindications. There is limited safety data in this group	Ok for people whose immune function is lowered by HIV, immunosuppressing drugs, or autoimmune disease. People with these conditions may still get the vaccine if they have no other contraindications. There is limited safety data in this group	Not yet available	Not yet available

